Business Description
Vistagen Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92840H4002
Total Employee Number:
59Description
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 43.49 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -17.2 | |||||
Beneish M-Score | -1.31 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 39.4 | |||||
3-Year EPS without NRI Growth Rate | 40.1 | |||||
3-Year FCF Growth Rate | 37.5 | |||||
3-Year Book Growth Rate | -18.4 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 89.59 | |||||
9-Day RSI | 68.8 | |||||
14-Day RSI | 58.24 | |||||
3-1 Month Momentum % | -0.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.67 | |||||
Quick Ratio | 3.67 | |||||
Cash Ratio | 3.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -75.6 | |||||
Shareholder Yield % | -329.63 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -5678.74 | |||||
Net Margin % | -5487.01 | |||||
EBITDA Margin % | -5621.02 | |||||
FCF Margin % | -5279.31 | |||||
OCF Margin % | -5267.15 | |||||
ROE % | -124.47 | |||||
ROA % | -100.18 | |||||
ROIC % | -1213.53 | |||||
3-Year ROIIC % | 1659.1 | |||||
ROC (Joel Greenblatt) % | -4632.58 | |||||
ROCE % | -126.94 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 6.85 | |||||
PB Ratio | 0.25 | |||||
Price-to-Tangible-Book | 0.25 | |||||
EV-to-EBIT | 0.49 | |||||
EV-to-EBITDA | 0.49 | |||||
EV-to-Revenue | -27.63 | |||||
EV-to-FCF | 0.53 | |||||
Price-to-GF-Value | 0.1 | |||||
| Price-to-Net-Current-Asset-Value | 0.26 | |||||
| Price-to-Net-Cash | 0.28 | |||||
Earnings Yield (Greenblatt) % | 204.08 | |||||
FCF Yield % | -718.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vistagen Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 23.147 | ||
| EPS (TTM) (MXN) | -33.626 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 58.24 | ||
| 14-Day ATR (MXN) | 0.002758 | ||
| 20-Day SMA (MXN) | 10.65 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (MXN) | 10.1 - 11.54 | ||
| Shares Outstanding (Mil) | 41.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vistagen Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vistagen Therapeutics Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-13 17:00 | In 136 days | ||
| Second quarter earnings results for 2027 | 2026-11-13 | In 135 days | ||
| General meeting for 2026 | 2026-09-09 09:00 | In 71 days | ||
| First quarter earnings conference call for 2027 | 2026-08-07 17:00 | In 38 days | ||
| First quarter earnings results for 2027 | 2026-08-07 | In 37 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-06-24 17:00 | 10.65 (+0.00%) | ||
| Annual report for 2026 | 2026-06-15 | 10.65 (+0.00%) | ||
| Fourth quarter earnings results for 2026 | 2026-06-15 | 10.65 (+0.00%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-20 14:35 | 10.65 (+0.00%) | ||
| Guidance call for 2026 | 2026-03-17 09:00 | 11.15 (+0.00%) |
Show
Entries
Vistagen Therapeutics Inc Frequently Asked Questions
What is Vistagen Therapeutics Inc(MEX:VTGN)'s stock price today?
The current price of MEX:VTGN is MXN10.65. The 52 week high of MEX:VTGN is MXN11.54 and 52 week low is MXN10.10.
When is next earnings date of Vistagen Therapeutics Inc(MEX:VTGN)?
The next earnings date of Vistagen Therapeutics Inc(MEX:VTGN) is 2026-08-07 Est..
Does Vistagen Therapeutics Inc(MEX:VTGN) pay dividends? If so, how much?
Vistagen Therapeutics Inc(MEX:VTGN) does not pay dividend.
Press Release
Articles on Vistagen Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers